PHAS Insider Trading Activity and SEC Form 4 Filings
PHAS insider trading summary
No open-market insider purchases or sales of PhaseBio Pharmaceuticals Inc (PHAS) have been reported on SEC Form 4 in the past 12 months.
Latest PHAS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 25, 2022 | Forest Baskett | 10% Owner | Sell | $262K (1,784,109 @ $0.15) |
| Oct 25, 2022 | NEA Partners 13, Limited Partnership | 10% Owner | Sell | $262K (1,784,109 @ $0.15) |
| Oct 25, 2022 | New Enterprise Associates 13 LP | 10% Owner | Sell | $262K (1,784,109 @ $0.15) |
| Oct 25, 2022 | Patrick J Kerins | 10% Owner | Sell | $262K (1,784,109 @ $0.15) |
| Oct 25, 2022 | NEA 13 GP, Ltd | 10% Owner | Sell | $262K (1,784,109 @ $0.15) |
| Oct 25, 2022 | Scott D Sandell | 10% Owner | Sell | $262K (1,784,109 @ $0.15) |
| May 23, 2022 | Glen Burkhardt | SVP of Human Resources | Sell | $9K (11,248 @ $0.79) |
| Nov 19, 2021 | Glen Burkhardt | VP, Human Resources | Sell | $14K (5,766 @ $2.37) |
| Aug 18, 2021 | Nancy J Hutson | Director | Buy | $9K (3,000 @ $3.08) |
| Aug 18, 2021 | Clay Thorp | Director | Buy | $30K (10,000 @ $3.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.